SCHEMBL1034632

SCHEMBL1034632

CN(C(=O)C1CC1)c1cccc(-c2ccnc(NC3CCCCC3)n2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 2/20 0.51
DGAT1 O75907 1/20 0.47
CDK1 P06493 8/20 0.45
CCNB1 P14635 8/20 0.45
CCNB2 O95067 5/20 0.45
CCNB3 Q8WWL7 5/20 0.45
CDC7 O00311 1/20 0.44
PLK4 O00444 1/20 0.44
JAK2 O60674 1/20 0.44
MAP4K4 O95819 1/20 0.44
INSR P06213 1/20 0.44
CSF1R P07333 1/20 0.44
PIM1 P11309 1/20 0.44
PRKACA P17612 1/20 0.44
FLT1 P17948 1/20 0.44
TYK2 P29597 1/20 0.44
KDR P35968 1/20 0.44
FLT3 P36888 1/20 0.44
GSK3B P49841 1/20 0.44
JAK3 P52333 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1034911 0.81 ROCK2 (0.57) HDAC8DGAT1CDK1CCNB1CCNB2
SCHEMBL1032555 0.80 HDAC8 (0.47) HDAC8DGAT1CDK1CCNB1CCNB2
SCHEMBL1032453 0.78 ABL1 (0.66) DGAT1CDK1CCNB1CCNB2CCNB3
SCHEMBL1030447 0.78 MAPK14 (0.52) HDAC8DGAT1CDK1CCNB1CCNB2
SCHEMBL1033626 0.77 CDK1 (0.53) DGAT1CDK1CCNB1CCNB2CCNB3
SCHEMBL1034808 0.76 AURKA (0.55) HDAC8DGAT1MAP4K4MAPK8ROCK2
SCHEMBL1028968 0.75 MAP4K4 (0.55) DGAT1CDK1CCNB1CCNB2CCNB3
SCHEMBL1030530 0.75 ADORA1 (0.59) HDAC8DGAT1CDK1CCNB1CCNB2
SCHEMBL3619159 0.75 ADORA1 (0.59) HDAC8DGAT1CDK1CCNB1CCNB2
SCHEMBL1033479 0.75 PTGS2 (0.55) CDK1CCNB1CCNB2CCNB3CDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011008931-A2 ARYLPYRIMIDINE COMPOUNDS AND COMBINATION THERAPY COMPRISING SAME FOR TREATING CYSTIC FIBROSIS & RELATED DISORDERS CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2011-01-20 WO claimed
WO-2010151747-A1 PYRIMINE COMPOUNDS AND METHODS OF MAKING AND USING SAME CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2010-12-29 WO claimed
WO-2011008931-A2 ARYLPYRIMIDINE COMPOUNDS AND COMBINATION THERAPY COMPRISING SAME FOR TREATING CYSTIC FIBROSIS & RELATED DISORDERS CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2011-01-20 WO disclosed
WO-2011008931-A2 ARYLPYRIMIDINE COMPOUNDS AND COMBINATION THERAPY COMPRISING SAME FOR TREATING CYSTIC FIBROSIS & RELATED DISORDERS CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2011-01-20 WO disclosed
WO-2010151747-A1 PYRIMINE COMPOUNDS AND METHODS OF MAKING AND USING SAME CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2010-12-29 WO disclosed
WO-2010151747-A1 PYRIMINE COMPOUNDS AND METHODS OF MAKING AND USING SAME CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2010-12-29 WO disclosed